8 results about "Endothelial cell apoptosis" patented technology

The invention discloses an application of rhBMP9 in preparation of a medicine for treating idiopathic pulmonary fibrosis related pulmonary arterial hypertension, the rhBMP9 protects pulmonary vascular endothelial cells, inhibits endothelial cell apoptosis and improves pulmonary vascular remodeling by up-regulating BMP9 / BMPR2 / SMAD signal pathways so as to treat IPF-PH, the invention further provides various dosage forms and administration routes of the rhBMP9 medicine, and the rhBMP9 medicine can be used for preparing the medicine for treating the idiopathic pulmonary fibrosis related pulmonary arterial hypertension. According to the application of the rhBMP9 and the drug combination scheme of the rhBMP9 and other IPF treatment drugs, animal experiments show that the rhBMP9 can remarkably improve hemodynamic parameters and lung tissue pathological changes of an IPF-PH model, and a new strategy is provided for clinical treatment of IPF-PH.

The invention belongs to the field of biological medicine, and particularly relates to an application of rose natural extracellular vesicles in preparation of cardiovascular protection products, the rose extracellular vesicles are extracted through a classical ultracentrifugation method, biological characteristics of the rose extracellular vesicles are identified and confirmed through a transmission electron microscope (a tea tray type nano vesicle structure) and a nano-particle tracking analyzer (80-150 nm, 1.8 E + 11 Particle / mL) in a combined mode, and the application of the rose extracellular vesicles in preparation of cardiovascular protection products is achieved. After research, it is found that when the rose extracellular vesicles are applied to cardiovascular products, the rose extracellular vesicles have the effects of (a) promoting endothelial cell proliferation; (b) inhibiting endothelial cell apoptosis; and (c) a function of enhancing oxidation resistance. The invention verifies the application of the rose natural extracellular vesicles, and the experimental research finds that the rose extracellular vesicles as a natural active ingredient have a remarkable effect in synchronous triple regulation (proliferation promotion-apoptosis resistance-oxidation resistance) of human umbilical vein endothelial cells (HUVEC), and can be used for preparing the rose natural extracellular vesicles. And a new way is provided for developing non-engineering cardiovascular protection products with high safety performance.

The invention discloses application of INO80E in preparation of an anti-atherosclerosis medicine, and belongs to the technical field of biological medicines. The invention reveals for the first time that INO80E can interact with histone deacetylase 1 (HDAC1) so as to deacetylate a transcription factor YY1, so that vascular endothelial cell apoptosis is inhibited, and the purpose of delaying an atherosclerosis process is achieved. Experiments prove that the expression level of INO80E in an atherosclerosis model is remarkably reduced; overexpression of INO80E can effectively reverse endothelial cell apoptosis induced by oxidized low-density lipoprotein (ox-LDL) and restore expression balance of anti-apoptotic protein Bcl-2 and pro-apoptotic protein BAX. Therefore, the INO80E can be used as a brand new drug target for treating or preventing atherosclerosis related diseases, can be used for preparing diagnostic reagents or drugs, and has the advantages of no equipment dependence and strong targeting.

This invention discloses a mitochondrial uncoupling agent prodrug with endothelial cell targeting, its preparation method, and its application, relating to the field of biomedical technology. The prodrug is covalently coupled to a vascular cell adhesion molecule-1 targeting polypeptide (amino acid sequence FAKELMEEFEKW), a reactive oxygen species-sensitive thioacetate linker, and the mitochondrial uncoupling agent OPC-163493. This invention utilizes the active enrichment effect of the targeting polypeptide on inflamed pulmonary vascular endothelial cells, overcoming the off-target defects of non-specific distribution in existing small molecule drugs; simultaneously, it utilizes the specific cleavage characteristics of the thioacetate linker in a microenvironment rich in reactive oxygen species to achieve precise in-situ drug release. This prodrug can effectively reduce mitochondrial reactive oxygen species generation, inhibit endothelial cell apoptosis, significantly reduce pulmonary vascular permeability, and alleviate pulmonary edema, possessing significant clinical application value in the preparation of drugs for treating acute lung injury or acute respiratory distress syndrome.

The invention belongs to the technical field of preparation of fermented biogen, and particularly relates to lactobacillus rhamnosus fermented biogen, a preparation method of the lactobacillus rhamnosus fermented biogen and application of the lactobacillus rhamnosus fermented biogen to improvement of atherosclerosis, reduction of thrombosis risk and regulation of ceramide metabolism. In the preparation process of the lactobacillus fermented biogen, yeast protein releases polypeptide with vasodilation and inflammation inhibition functions, and after the polypeptide is matched with anthocyanin and araboxylan oligosaccharide which have the functions of regulating ceramide metabolism and protecting the cardiovascular system, the activity of the polypeptide is improved; under the fermentation action of the lactobacillus rhamnosus NKU ML1-2, lactobacillus fermentation postbiotics with the function of protecting heart and cerebral vessels are formed, and the lactobacillus fermentation postbiotics as a dietary nutrition intervention means can directly act on vascular cells through multiple ways to promote the function repair of endothelial cells; apoptosis and oxidative damage of endothelial cells are inhibited, generation of ceramide substances is regulated, and an innovative nutrition intervention strategy is provided for prevention and treatment of atherosclerosis related diseases and prevention of thrombosis.

The invention provides application of xanthoxylin in preparation of a medicine for relieving atherosclerosis, and belongs to the technical field of medicines.The research finds that xanthoxylin relieves atherosclerosis by inhibiting endothelial cell apoptosis, and further research shows that xanthoxylin up-regulates miR-26a by inhibiting expression of methyltransferase DNMT, so that the atherosclerosis is relieved. Further, the target gene TRPC6 is down-regulated, and the concentration of calcium ions in cells is reduced; that is, research finds that the xanthoxylin inhibits endothelial cell apoptosis and relieves atherosclerosis through the DNMT / miR-26a / TRPC6 pathway, and a theoretical basis is provided for the medicinal value of the xanthoxylin.

The invention discloses a traditional Chinese medicine composition for treating breast cancer and a preparation and application thereof, and belongs to the technical field of traditional Chinese medicine and network pharmacology. The traditional Chinese medicine composition comprises the following raw material medicines: radix bupleuri, angelica sinensis, radix paeoniae alba, radix curcumae, dandelion, uniflower swisscentaury root, sculellaria barbata, selfheal, rhizoma bolbostemmae, thunberg fritillary bulb, spina gleditsiae, turtle shell, salvia miltiorrhiza and glossy privet fruit. The main effective components of the traditional Chinese medicine composition are quercetin, luteolin, kaempferol, beta-sitosterol and the like, and can participate in conduction of Hippo, TGF-beta, axon guidance, tight junction, vascular smooth muscle contraction and other signal channels through PTGS2, PTGS1, NCOA2, ADRB2 and other targets. Further, the anti-tumor effect is achieved in the biological processes of positively regulating cell growth, negatively regulating and controlling an external apoptosis signal path through a death structural domain receptor, positively regulating an endothelial cell apoptosis process, reaction to cytokines, an internal apoptosis signal path, a hormone-mediated signal transduction path and the like.

The invention provides inflammation-targeted immunoregulation hydrogel microspheres as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. According to the invention, an injectable mND13 peptide coupled HAMA microsphere (mND13 at HAMA) is designed through a microfluid technology, and the injectable mND13 peptide coupled HAMA microsphere (mND13 at HAMA) can be used for training immune behaviors of microglia for a long time while interacting with a blood vessel microenvironment. As a medium of cell-microenvironment crosstalk, the immunomodulatory factor mND13 is continuously isolated and released, proinflammatory microglial cells are inhibited, blood vessels are protected, and angiogenesis is promoted. This multifunctional microsphere allows for the co-loading of other therapeutic agents in a combination therapy strategy. In an in-vitro cell model and an in-vivo cerebral apoplexy model, the compound system can obviously down-regulate proinflammatory factors (IL-1beta, iNOS, CD86 and IL-6), reduce endothelial cell apoptosis, improve local vascular microenvironment, reduce encephalatrophy volume and improve neurobehavior results of cerebral apoplexy mice.